Auflistung Nach Schlagwort "Natalizumab"

Sortiert nach: Sortierung: Ergebnisse:

  • Espectro clínico de la leucoencefalopatía multifocal progresiva: diferencias y similitudes en pacientes con y sin virus de la inmunodefi ciencia humana 
    Camporro, Julieta; Bruno, Verónica; Cammarota, Ángel Norberto; Del Castillo, Marcelo Ernesto; Alessandro, Lucas (Viguera, 2019-08-16)
    Objetivo. Analizar los hallazgos clínicos, exámenes complementarios y pronóstico de los pacientes con leucoencefalopatía multifocal progresiva (LMP) atendidos en nuestra institución, comparando las poblaciones con y sin ...
  • Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile 
    Ysrraelit, María Célica; Caride, Alejandro; Sinay, Vladimiro; Rivera Kindel, Mario; Halfon, Mario Javier; Patrucco, Liliana; Piedrabuena, Raúl; Diaz Aragunde, Vanina Eleonor (Associacao Arquivos De Neuro-Psiquitria Dr Oswaldo Lange, 2021-05-01)
    Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported. Objective: To evaluate the effectiveness of natalizumab treatment ...
  • Rebound activity after fingolimod cessation: A case - control study 
    Barboza, Andrés G.; Gaitán, María Inés; Alonso, Ricardo; Ysrraelit, María Célica; Luetic, Geraldine G.; Liwacki, Susana; Patrucco, Liliana; Halfon, Mario Javier; Burgos, Marcos; Mainella, Carolina; Piedrabuena, Raúl; Recchia, Luciano; Steinberg, Judith; Tkachuk, Verónica A.; Zanga, Gisela; Carra, Adriana; Chertcoff, Aníbal; Fernández Liguori, Nora; Lázaro, Luciana; Menichini, María Laura (Elsevier, 2022-02-09)
    Background: There has been an increase in the number of reports of multiple sclerosis (MS) rebound activity (RA), which is usually defined as a severe disease reactivation after natalizumab or fingolimod withdrawal that ...

DSpace Suche

Stöbern

Mein Benutzerkonto